Compass Therapeutics, Inc. (CMPX) stock

CMPXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 9, 2026Score 7/30

$0.82−0.01 (-1.23%)

Close on Nov 12, 2026Market cap $147.67MP/E –Yield –

Compass Therapeutics price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Compass Therapeutics's price to sales ratio was 301.6× on Apr 30, 2025.

Period	Period end	Value	Change (pts)
2025	Apr 30, 2025	301.6×	–

Parsed from the XBRL in Compass Therapeutics's annual and quarterly filings with the SEC
Per-share figures adjusted for the 4-for-3 split on Aug 13, 2020
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is CMPX.

Advertisement
300 × 250

See a number that looks wrong?